Genomic Health Announces Preliminary Results From A Study Of Oncotype DX(TM) In Node-Positive Breast Cancer Patients
Oct 20th 2007Drug InformationEndocrinology
Genomic Health, Inc. (Nasdaq: GHDX) announced encouraging results from a study of Oncotype DX in postmenopausal women with node-positive, hormone receptor positive breast cancer conducted by the Southwest Oncology Group (SWOG), a National Cancer Institute clinical trials cooperative group. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
